ECE2022 Eposter Presentations Endocrine-Related Cancer (61 abstracts)
Poor outcome of systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
Kazhan Mollazadegan 1 , Britt Skogseid 1 , Johan Botling 2 , Tobias Ækerström 3 , Barbro Eriksson 1 , Staffan Welin 1 , Sundin Anders 3 & Joakim Crona 1
1Uppsala University, Department of Medical Sciences, Uppsala, Sweden; 2Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden; 3Uppsala University, Department of Surgical Sciences, Uppsala, Sweden
Introduction: Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3, that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown.
Methods: This was a single center retrospective cohort study, aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed utilizing the Response Evaluation Criteria in Solid Tumors version 1.1.
Results: A total of 22 patients were included and received a median of 2 (range 1-4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25-17.5). For the 15 patients who received platinum-etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75-10) and median progression-free survival (PFS) was 4 months (IQR: 2.5-5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR:5-16.75) and median PFS was 5.5 months (IQR:2.75-8.25). We observed one partial response on 177Lu DOTA-TATE therapy.
Conclusion: In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more